Glaucoma affects 2.7 million Americans aged 40 and over. While this eye condition is often associated with age, glaucoma can develop earlier.
In fact, it can start developing in someone’s forties. Glaucoma has few noticeable symptoms and is often diagnosed once vision loss occurs.
Glaucoma is a degenerative eye disease. Untreated glaucoma will result in eventual blindness, but the condition is treatable! Keep reading to learn more about this eye condition!
Glaucoma is one of the leading causes of blindness
Glaucoma is one of the top causes of blindness worldwide and is second behind cataracts. Glaucoma affects about 2.7 million Americans. Cataracts affect 24.4 million Americans.
Both conditions begin developing as early as a patient’s forties. The big difference between cataracts and glaucoma is there’s no cure for glaucoma. If someone has a cataract, they can have it removed by undergoing cataract surgery.
Vision lost to glaucoma can’t be restored
Early detection and glaucoma treatment is key to minimizing vision loss. Unfortunately, any vision lost to glaucoma is gone for good.
It’s only through regular eye examinations that you can stay ahead of glaucoma. If you are diagnosed with glaucoma early, there are treatment options to consider.
With an early diagnosis, you can save more of your vision being lost to glaucoma. This makes it essential for adults who are 40 and over to see their eye doctors regularly. With comprehensive eye exams, you can stay a step ahead of glaucoma!
Why a dilated eye examination is so important
Your eye doctor will need to dilate your eyes during your eye examination. By dilating your eyes, it is the best way to detect early-stage glaucoma.
Without dilation, the chances are high your eye doctor could miss signs of glaucoma. Nobody likes getting their eyes dilated, but it’s a necessary part of getting eye exams!
How often do you need an eye examination?
How often you will need your eyes examined depends on both your age and your risk level. It’s best to discuss this with your eye doctor.
If you know that you are “high risk” for developing glaucoma, you should go at least every one to two years. For people that are not at high risk, you should still go every few years.
Ultimately, ask your eye doctor if you’re unsure about how often to get a comprehensive eye exam.
Who is at risk?
The simple truth is that every adult 40 and over is at risk of developing glaucoma. Higher risk individuals are people who have a family history of glaucoma.
Other people at higher risk are those that are of African American or Hispanic descent. If you have a condition like high blood pressure or diabetes, you are also at a higher risk for glaucoma.
It’s rare, but babies and young children can also develop congenital glaucoma.
Glaucoma treatment options
Glaucoma might be one of the top causes of blindness, but it is also very treatable in its early stages.
Treatment options include prescribed eye drops, special pills, and laser eye surgical procedures. How your glaucoma will be treated depends on how severe your intraocular pressure is.
Concerned that you may have lost vision due to glaucoma? Schedule a consultation at Takle Eye Group in Griffin, Georgia today!
Takle Eye Group is proud to present our newest procedure for patients who have cataracts and are also managing glaucoma. iStent® Trabecular Micro-Bypass is the first microinvasive glaucoma surgery (MIGS) device to safely reduce pressure in the eye by creating a permanent opening in the drainage network around the eye (called the trabecular meshwork).
The iStent® is the smallest ever FDA-approved medical device. It’s a snorkel-like tube that’s inserted into the trabecular meshwork during cataract surgery. No additional procedure is necessary. Once inserted, iStent® helps manage the flow of aqueous humor – the fluid in your eye – so that excess pressure in the eye is reduced and the danger of permanent damage is lessened.
iStent® may also decrease the need for some glaucoma medications prescribed to you, though this is at the discretion of your doctor.
If you have glaucoma, are planning for cataract surgery, and would like to discuss iStent® as a potential treatment option, contact us for a consultation at http://www.takleeye.com/contact-us/ or by calling 770-228-3836.
For more information on glaucoma, visit our glaucoma center or read our previous article about the two kinds of glaucoma.
INDICATION FOR USE
The iStent® Trabecular Micro-Bypass Stent (Models GTS100R and GTS100L) is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate open-angle glaucoma currently treated with ocular hypotensive medication.
The iStent is contraindicated in eyes with primary or secondary angle closure glaucoma, including neovascular glaucoma, as well as in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.
Gonioscopy should be performed prior to surgery to exclude PAS, rubeosis, and other angle abnormalities or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard. The iStent is MR-Conditional meaning that the device is safe for use in a specified MR environment under specified conditions, please see label for details.
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the iStent has not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, chronic inflammation, or an abnormal anterior segment, in pseudophakic patients with glaucoma, in patients with pseudoexfoliative glaucoma, pigmentary, and uveitic glaucoma, in patients with unmedicated IOP less than 22 mmHg or greater than 36 mmHg after ?washout? of medications, or in patients with prior glaucoma surgery of any type including argon laser trabeculoplasty, for implantation of more than a single stent, after complications during cataract surgery, and when implantation has been without concomitant cataract surgery with IOL implantation for visually significant cataract.
The most common post-operative adverse events reported in the randomized pivotal trial included early post-operative corneal edema (8%), BCVA loss of = 1 line at or after the 3 month visit (7%), posterior capsular opacification (6%), stent obstruction (4%) early post-operative anterior chamber cells (3%), and early post-operative corneal abrasion (3%). Please refer to Directions for Use for additional adverse event information.
Federal law restricts this device to sale by, or on the order of, a physician. Please reference the Directions for Use labeling for a complete list of contraindications, warnings, precautions, and adverse events.